Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | TDP2 | O95551 | 2/20 | 0.30 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL90933 | 0.76 | MMP12 (0.36) | — | |
| SCHEMBL994489 | 0.76 | MAPT (0.44) | — | |
| SCHEMBL1046470 | 0.76 | ALOX5 (0.30) | ALOX5ABCG2 | |
| SCHEMBL5373991 | 0.76 | ALOX5 (0.30) | ALOX5ABCG2 | |
| SCHEMBL3331065 | 0.76 | CYP3A4 (0.55) | — | |
| SCHEMBL30338444 | 0.76 | APEX1 (0.34) | — | |
| SCHEMBL1906239 | 0.76 | BLM (0.46) | PNMT | |
| SCHEMBL1669250 | 0.72 | CHRM2 (0.41) | ADRA2APNMTADRA2BADRA2C | |
| SCHEMBL700254 | 0.72 | CYP3A4 (0.40) | — | |
| SCHEMBL29575727 | 0.72 | ALOX15B (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | MAPK3, MAPK1, MAPKAPK3 | ADRA2A 2051/4885PNMT 3662/4885ADRA2B 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.